Monthly ReportMay 1–31, 2025
Sepsis, May 2025 edition
We read 105 papers and selected 5.
Summary
May 2025 sepsis research showed a strong shift toward precision, mechanism-informed care, combining high-quality clinical trials with deployable diagnostics and host-directed therapeutic discovery. Hemodynamic management was directly challenged by the OPTPRESS randomized trial, which demonstrated harm from higher MAP targets in older patients with septic shock, while the A2B trial refined sedation practice by supporting propofol over alpha-2 agonists for ventilated ICU patients. Translational studies identified new host-defense pathways involving nuclear stress bodies/NFIL3, hepatic Nrf1-lipid metabolism, mitochondrial dysfunction, and immune-cell regulation. Diagnostic development progressed from metabolomic and genomic risk markers to bedside microfluidic transcriptomic testing capable of predicting near-term deterioration. Overall, the field is converging on earlier risk stratification, individualized organ-support targets, rapid pathogen characterization, and adjunctive therapies that modulate host tolerance without broadly suppressing immunity.
Selected Articles
1. De novo assembly of nuclear stress bodies rearranges and enhances NFIL3 to restrain acute inflammatory responses.
This study demonstrates that stress-induced nuclear stress bodies reorganize SatIII loci and recruit transcriptional machinery to increase NFIL3 expression. NFIL3 suppresses proinflammatory cytokine production, and activation of the NFIL3/SatIII program in patient PBMCs correlates with survival in sepsis. The work connects chromatin architecture and cellular stress responses with clinically relevant immune restraint.
Impact: It reveals a previously underappreciated chromatin-based mechanism of immune restraint and links the molecular pathway to patient survival, creating both a prognostic biomarker concept and a potential host-directed therapeutic axis.
Clinical Implications: NFIL3 and SatIII activation could be evaluated as markers of an adaptive immune-restraint state and may help distinguish patients at risk of uncontrolled inflammation. Therapeutic manipulation of nuclear stress-body components remains investigational and requires validation in clinically relevant sepsis models.
Key Findings
- Stress-induced nuclear stress bodies expand SatIII loci and enhance NFIL3 expression.
- NFIL3 suppresses proinflammatory cytokine production through chromatin and transcriptional regulation.
- NFIL3/SatIII activation in patient PBMCs correlates with survival in sepsis.
2. Multi-Omics and -Organ Insights into Energy Metabolic Adaptations in Early Sepsis Onset.
This cross-species study integrated serum metabolomics and lipidomics from 152 presymptomatic surgical patients with single-nucleus RNA sequencing in a mouse sepsis model. Serine and aminoadipic acid distinguished uncomplicated infection from sepsis, while mitochondrial energy genes including Cox4i1, Cox8a, and Ndufa4 were downregulated. The results link early systemic metabolite changes with organ-level mitochondrial dysfunction and identify serine-centered metabolism as a candidate early-warning pathway.
Impact: It bridges presymptomatic human biomarker discovery with mechanistic animal validation and provides a biologically coherent framework for detecting sepsis before overt clinical deterioration.
Clinical Implications: A serine-centered metabolite panel could eventually support postoperative and emergency risk stratification if externally validated. The mitochondrial findings also suggest potential metabolic interventions, but assay standardization, confounding by surgery and nutrition, and prospective clinical utility require clarification.
Key Findings
- Serine and aminoadipic acid discriminated postoperative uncomplicated infection from sepsis.
- Mitochondrial energy genes including Cox4i1, Cox8a, and Ndufa4 were downregulated in the mouse model.
- Liver-specific serine-related metabolic changes linked circulating biomarkers to organ-level bioenergetic dysfunction.
3. Efficacy of targeting high mean arterial pressure for older patients with septic shock (OPTPRESS): a multicentre, pragmatic, open-label, randomised controlled trial.
OPTPRESS randomized 518 patients aged 65 years or older with septic shock to MAP targets of 80–85 mmHg or 65–70 mmHg. The trial was stopped early for harm: 90-day mortality was 39.3% versus 28.6% in the high- and standard-target groups, respectively. No subgroup, including patients with chronic hypertension, benefited from the higher target, and renal replacement therapy–free days were reduced.
Impact: This is the month’s most practice-changing randomized evidence for septic shock management, directly challenging the assumption that higher perfusion pressure is broadly beneficial in older patients.
Clinical Implications: For older adults with septic shock, clinicians should generally avoid routine MAP targets of 80–85 mmHg and use approximately 65–70 mmHg unless individualized circumstances justify otherwise. Higher vasopressor exposure should be accompanied by close assessment of renal function, ischemia, arrhythmia, and other adverse effects.
Key Findings
- The trial was stopped early because the high-MAP strategy increased harm.
- Ninety-day mortality was 39.3% with MAP 80–85 mmHg versus 28.6% with MAP 65–70 mmHg.
- No subgroup, including patients with chronic hypertension, benefited from the higher MAP target.
4. A machine learning and centrifugal microfluidics platform for bedside prediction of sepsis.
The investigators developed a six-gene Sepset signature to predict clinical deterioration within 24 hours. The model was derived from 586 samples and externally validated in 3,178 patients. Translation into RT-PCR and an automated centrifugal microfluidic device achieved approximately 92–94% sensitivity and 89% specificity, demonstrating a practical route from transcriptomic discovery to point-of-care risk assessment.
Impact: It converts a complex molecular risk signature into a deployable bedside platform, directly addressing the time-sensitive need to identify patients likely to deteriorate before overt organ failure.
Clinical Implications: Prospective implementation could support earlier ICU referral, intensified monitoring, and more timely antimicrobial and organ-support decisions. Before routine adoption, analytical reproducibility, workflow integration, cost-effectiveness, and impact on patient outcomes must be evaluated.
Key Findings
- A six-gene Sepset signature predicted 24-hour clinical deterioration.
- The classifier was externally validated in 3,178 patients.
- The automated microfluidic RT-PCR platform achieved approximately 92–94% sensitivity and 89% specificity.
5. Hepatic Nuclear Factor Erythroid 2 Related Factor 1 Activity Promotes Host Defense in Endotoxemia and Bacterial Sepsis.
In murine endotoxemia and bacterial sepsis models, hepatic Nrf1 activity protected against hypothermia and mortality by maintaining VLDL secretion and triglyceride handling. Inhibition of lipid export abolished protection, whereas lipid infusion restored survival. The findings identify hepatic lipid flux as a host-tolerance mechanism distinct from the better-known Nrf2 pathway.
Impact: The study identifies a mechanistically tractable metabolic defense pathway that links liver lipid export to survival, expanding sepsis research beyond inflammation and toward host-tolerance physiology.
Clinical Implications: The findings support future evaluation of hepatic Nrf1 activity, lipid metabolism, and tailored lipid-support strategies as adjunctive approaches. Translation must address the risks of lipid administration, metabolic heterogeneity, organ dysfunction, and timing during sepsis.
Key Findings
- Hepatic Nrf1 deficiency caused severe hypothermia and increased mortality in sepsis models.
- Nrf1 maintained VLDL secretion and triglyceride metabolism as a protective host response.
- Blocking lipid export worsened outcomes, whereas lipid infusion rescued experimental sepsis.